Fasenra

This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.

Nucala works in rare inflammatory disease, says GSK

GSK is trying to keep the first-to-market IL-5 inhibitor ahead of other drugs in the class, particularly AstraZeneca’s Fasenra (benralizumab) which is gaining ground fast with

Latest news

AZ reports growth again in Q3, driven by oncology and China sales

AZ’s respiratory franchise also grew 18% to $1.3bn – although the company saw a 4% decline in sales of Symbicort, this was offset by the growth of Pulmicort and Fasenra,
Tecentriq’s triple negative breast cancer use among key CHMP nods

The company also received a positive opinion for a new self-administration option for Fasenra (benralizumab) via a pre-filled, single-use auto-injector, rivalling similar moves from GSK and its
GSK’s Nucala gets boost with self-administration approval

it. This still leaves it at a disadvantage to Fasenra, which is administered just once every eight weeks. ... This bad news has been tempered by disappointing results for AZ's rival Fasenra in the same setting.
Sanofi's Dupixent gains asthma approval in Europe

This puts it into direct competition with some established players in that field, GSK's Nucala and AstraZeneca's Fasenra..
AZ says dropping MedImmune will help ‘streamline’ its R&D

The Gaithersburg, Maryland-headquartered company is the source of a chunk of AZ’s biologics pipeline, including cancer immunotherapy Imfinzi (durvalumab) and severe asthma drug Fasenra (benralizumab) that were both highlighted

More from news
Approximately 7 fully matching, plus 16 partially matching documents found.

Latest Intelligence

The long and winding road to asthma breakthroughs

But GSK is not alone in the IL-5 inhibitor arena. AstraZeneca’s Fasenra is making waves with its eight-week dosing schedule and $296m in first-half sales – a 244%
AstraZeneca: building a new ‘open innovation’ pharma company

AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO

Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Director, Medical Education: Salary TBC

Account Executive: Salary TBC

Medical Writer – Very Flexible Working – Surrey: Negotiable

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Graduate Scientific Editor: DOE

Account Director: Salary TBC

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Senior Medical Writer: Salary TBC

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Account Supervisor: Salary TBC

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Subscribe to our email news alerts

PMHub

Add my company

JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Using human insights to push healthcare communications forward: This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy: The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail: We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...